Back to results
US 2005/0118699 A1Published application
Packaging complementation cell-line for sv-40 vectors
OwnerAriella Oppenheim, Uri Aradinventors
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerAriella Oppenheim, Uri Aradinventors
Estimating the term…
The present invention relates to a complementation SV40 packaging cell line for in-trans complementation of viral T-antigen (T-Ag). This cell line eliminates the generation of viable virus carrying the T-Ag gene, by reducing homologous recombination in packaging process of an SV40 vector, wherein said cell line is transformed with at least one expression cassette having minimal sequence identity to SV40 sequences comprised within said SV40 viral vector. The expression cassette of the invention comprises nucleic acid encoding SV40 T-Ag under the control of a heterologous promoter, heterologous termination signal; and optionally additional operably linked control elements and/or selectable markers. The invention further relates to methods for the preparation of packaging cell line, processes for production of a safe preparation of SV40 viral vectors and compositions comprising the same.
A complementation SV40 packaging cell line for in-trans complementation of SV40 T-antigen (T-Ag), which cell line eliminates the generation of viable virus carrying the T-Ag gene, by reducing homologous recombination in packaging process of an SV40 vector, wherein said cell line is transformed with at least one expression cassette having minimal sequence identity to SV40 sequences comprised within said SV40 viral vector, said expression cassette comprising:
An expression cassette for the production of a complementation SV40 packaging cell line, having minimal sequence identity to SV40 sequences comprised within an SV40 viral vector, said expression cassette comprising:
The SV40 viral vector according to claim 28, wherein said therapeutic protein or peptide product is at least one of a therapeutic protein or peptide which is not expressed, is expressed in abnormally low amount, is expressed in defective form or is expressed in physiologically abnormal amount, in a target cell.
Dependencies are inferred from the claim text.